177 related articles for article (PubMed ID: 25373438)
1. Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial.
Rodger MA; Phillips P; Kahn SR; James AH; Konkle BA;
Thromb Haemost; 2015 Jan; 113(1):212-6. PubMed ID: 25373438
[TBL] [Abstract][Full Text] [Related]
2. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women.
Bauersachs RM; Dudenhausen J; Faridi A; Fischer T; Fung S; Geisen U; Harenberg J; Herchenhan E; Keller F; Kemkes-Matthes B; Schinzel H; Spannagl M; Thaler CJ;
Thromb Haemost; 2007 Dec; 98(6):1237-45. PubMed ID: 18064320
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period.
Bain E; Wilson A; Tooher R; Gates S; Davis LJ; Middleton P
Cochrane Database Syst Rev; 2014 Feb; (2):CD001689. PubMed ID: 24519568
[TBL] [Abstract][Full Text] [Related]
4. Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial of two doses.
Bleker SM; Buchmüller A; Chauleur C; Ní Áinle F; Donnelly J; Verhamme P; Jacobsen AF; Ganzevoort W; Prins M; Beyer-Westendorf J; DeSancho M; Konstantinides S; Pabinger I; Rodger M; Decousus H; Middeldorp S
Thromb Res; 2016 Aug; 144():62-8. PubMed ID: 27289488
[TBL] [Abstract][Full Text] [Related]
5. Personalized thromboprophylaxis using a risk score for the management of pregnancies with high risk of thrombosis: a prospective clinical study.
Dargaud Y; Rugeri L; Fleury C; Battie C; Gaucherand P; Huissoud C; Rudigoz RC; Desmurs-Clavel H; Ninet J; Trzeciak MC
J Thromb Haemost; 2017 May; 15(5):897-906. PubMed ID: 28231636
[TBL] [Abstract][Full Text] [Related]
6. Compression stockings in addition to low-molecular-weight heparin to prevent venous thromboembolism in surgical inpatients requiring pharmacoprophylaxis: the GAPS non-inferiority RCT.
Shalhoub J; Lawton R; Hudson J; Baker C; Bradbury A; Dhillon K; Everington T; Gohel MS; Hamady Z; Hunt BJ; Stansby G; Warwick D; Norrie J; Davies AH
Health Technol Assess; 2020 Dec; 24(69):1-80. PubMed ID: 33275096
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial.
Fowler RA; Mittmann N; Geerts WH; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
Trials; 2014 Dec; 15():502. PubMed ID: 25528663
[TBL] [Abstract][Full Text] [Related]
8. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study.
Francis CW; Kessler CM; Goldhaber SZ; Kovacs MJ; Monreal M; Huisman MV; Bergqvist D; Turpie AG; Ortel TL; Spyropoulos AC; Pabinger I; Kakkar AK
J Thromb Haemost; 2015 Jun; 13(6):1028-35. PubMed ID: 25827941
[TBL] [Abstract][Full Text] [Related]
9. A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT).
Noble SI; Nelson A; Fitzmaurice D; Bekkers MJ; Baillie J; Sivell S; Canham J; Smith JD; Casbard A; Cohen A; Cohen D; Evans J; Fletcher K; Johnson M; Maraveyas A; Prout H; Hood K
Health Technol Assess; 2015 Oct; 19(83):vii-xxiii, 1-93. PubMed ID: 26490434
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
[TBL] [Abstract][Full Text] [Related]
11. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
[TBL] [Abstract][Full Text] [Related]
12. Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters.
Schoot RA; Kremer LC; van de Wetering MD; van Ommen CH
Cochrane Database Syst Rev; 2013 Sep; (9):CD009160. PubMed ID: 24026801
[TBL] [Abstract][Full Text] [Related]
13. Development of the IRIS-AR strategy: an intervention to improve rates of accrual and retention for the VTE-PRO randomized controlled trial.
Fahim C; Hylton D; Simunovic M; Agzarian J; Finley C; Hanna WC; Shargall Y
Trials; 2019 Jul; 20(1):447. PubMed ID: 31324209
[TBL] [Abstract][Full Text] [Related]
14. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
[TBL] [Abstract][Full Text] [Related]
15. A risk score for the management of pregnant women with increased risk of venous thromboembolism: a multicentre prospective study.
Dargaud Y; Rugeri L; Vergnes MC; Arnuti B; Miranda P; Negrier C; Bestion A; Desmurs-Clavel H; Ninet J; Gaucherand P; Rudigoz RC; Berland M; Champion F; Trzeciak MC
Br J Haematol; 2009 Jun; 145(6):825-35. PubMed ID: 19388925
[TBL] [Abstract][Full Text] [Related]
16. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial.
Anderson DR; Dunbar MJ; Bohm ER; Belzile E; Kahn SR; Zukor D; Fisher W; Gofton W; Gross P; Pelet S; Crowther M; MacDonald S; Kim P; Pleasance S; Davis N; Andreou P; Wells P; Kovacs M; Rodger MA; Ramsay T; Carrier M; Vendittoli PA
Ann Intern Med; 2013 Jun; 158(11):800-6. PubMed ID: 23732713
[TBL] [Abstract][Full Text] [Related]
17. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.
Rasmussen MS; Jørgensen LN; Wille-Jørgensen P
Cochrane Database Syst Rev; 2009 Jan; (1):CD004318. PubMed ID: 19160234
[TBL] [Abstract][Full Text] [Related]
18. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Leizorovicz A; Cohen AT; Turpie AG; Olsson CG; Vaitkus PT; Goldhaber SZ;
Circulation; 2004 Aug; 110(7):874-9. PubMed ID: 15289368
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, randomized controlled trial of the prevention of clinically important venous thromboembolism after isolated lower leg fractures.
Selby R; Geerts WH; Kreder HJ; Crowther MA; Kaus L; Sealey F;
J Orthop Trauma; 2015 May; 29(5):224-30. PubMed ID: 25900749
[TBL] [Abstract][Full Text] [Related]
20. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study.
van Es N; Di Nisio M; Bleker SM; Segers A; Mercuri MF; Schwocho L; Kakkar A; Weitz JI; Beyer-Westendorf J; Boda Z; Carrier M; Chlumsky J; Décousus H; Garcia D; Gibbs H; Kamphuisen PW; Monreal M; Ockelford P; Pabinger I; Verhamme P; Grosso MA; Büller HR; Raskob GE
Thromb Haemost; 2015 Nov; 114(6):1268-76. PubMed ID: 26271200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
